Le Lézard
Classified in: Health
Subjects: NEW PRODUCTS/SERVICES, HEALTH, MISCELLANEOUS, MISCELLANEOUS, Clinical Study

Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep


Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a groundbreaking human clinical trial of ergothioneine. A double-blinded placebo-controlled clinical trial sponsored by Blue California has shown that ErgoActive® ergothioneine supports aspects of cognitive function, memory, and sleep in healthy elderly subjects with subjective memory complaints.

"Blue California is proud to have sponsored such an important human study," said Linda May-Zhang, Ph.D., VP of Science and Innovation at Blue California. "We are pleased by the results showing improvements of cognitive function and ability to get to sleep in subjects consuming ErgoActive for four months."

Research has suggested that inadequate levels of ergothioneine are associated with a range of health problems, including cardiovascular disease, frailty, age-related cognitive decline, neurodegenerative diseases such as Parkinson's disease, and dementias such as Alzheimer's disease. Mushroom consumption and estimated dietary ergothioneine intake have previously been associated with reduced risk of cognitive decline and potentially longer lifespan.

Despite decades of preclinical research, association studies, and clinical studies conducted with mushrooms, it remained untested whether supplementation with pure ergothioneine can improve cognitive outcomes. Rigorous clinical studies were lacking. Today, Blue California has made a substantial advancement by sponsoring a double-blinded, placebo-controlled clinical study conducted at a national research institution.

Sharing his insights, Robert B. Beelman, Ph.D., Professor Emeritus of Food Science and Director of the Center for Plant and Mushroom Foods for Health at Pennsylvania State University, stated, "The results of this study provide important clinical evidence supporting the idea that ergothioneine is a ?longevity vitamin' that can help mitigate cognitive decline and sleep issues commonly associated with aging."

Blue California is a proud gold sponsor for the National University of Singapore's Center of Healthy Longevity global conference on Supplements for Healthy Longevity, held Feb. 29 - Mar. 2, 2024.

ErgoActive ergothioneine is made by precision fermentation with FDA-reviewed safety of GRAS. This ingredient is easy to formulate for dietary supplements, functional food and beverages, pet supplements, and cosmetics.

###

About Blue California Ingredients

Blue California is a science-driven, nature-inspired ingredient company dedicated to developing innovative solutions for health and well-being. We provide and manufacture clean, natural, and sustainable ingredients used in food, beverage, flavor, fragrance, dietary supplements, personal care, and cosmetic products.

With a commitment to rigorous scientific research, the company aims to address pressing concerns related to aging and healthspan.  For more information, visit https://bluecal-ingredients.com/ergothioneine.

ErgoActive® is a registered trademark of Blue California, Inc.

Ergothioneine is also referred to as L-Ergothioneine, (ET) and (ERG).

Attachments



These press releases may also interest you

at 16:20
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The...

at 16:15
eHealth, Inc. , a leading private online health insurance marketplace (the "Company"), today announced that on July 1, 2024, the Compensation Committee of its Board of Directors granted inducement stock unit awards to two new employees covering an...

at 16:10
bluebird bio, Inc. today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James...

at 16:10
The global consumer healthcare market size is estimated to grow by USD 170.2 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.78% during the forecast period. Awareness about lifestyle diseases is driving...

at 16:05
Voomtm Medical Devices, Inc. ("Voom"), the orthopedic medical device company behind the disruptive, game-changing Revcontm bunion screw technology, is honored to be named first on Podiatry Today's 2024 Top 10 Innovations list. Voom's one-of-a-kind...

at 16:05
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation...



News published on and distributed by: